GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Commercials run by Hims & Hers advertise prescription injectable weight-loss drugs without disclosing safety and risk information.

The Janus Henderson Global Sustainable Equity Fund returned -5.88% for Q4 2024. Click here to read the full commentary.